Daily Topical Rapamycin for Vitiligo

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Vitiligo

In brief

In current Dermatology practice, options for vitiligo remain limited. The purpose of this study is to determine if once daily dosed topical rapamycin is effective for the treatment of patients with vitiligo. Participants will apply either 0.1% topical rapamycin or 0.001% topical rapamycin for six months to a lesion on one side of the body, and topical placebo to a corresponding lesion on the opposite side of the body. The study also aims to evaluate patient satisfaction and identify any adverse effects on these dosing regimens.

Key facts

Study ID

NCT05342519

Run by

Medical University of South Carolina

People needed

20

Starts

2022-07-28

Expected to finish

2027-12-01

Last updated by the study team

2026-03-05

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients 13 years of age and older
• Patients with nonsegmental vitiligo

You may not qualify if…

• Patients with segmental or mucosal vitiligo
• Patients with contraindication to use of rapamycin
• Patients with history of transplant
• Patients with a history of natural immunodeficiency
• Patients with a history of artificially induced immunodeficiency
• Patients with a history of a serious or life-threatening infection
• Patients taking CYP3A4 inhibiting medications
• Patients taking strong CYP3A4 inducers
• Patients undergoing current treatment for vitiligo
• Women that are or may become pregnant

Where it is running

• Medical University of South Carolina — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.